ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Colgate Palmolive and Procter and Gamble in Gingivitis

Their studies and programs in Gingivitis, as the condition page counts them: each program at the phase its studies here reached, with their next primary completion here. Counts, not rankings.

At a glance

Studies each sponsor leads that are filed under Gingivitis, with the companies grouped under it. Every number opens the studies it counts.

Colgate PalmoliveProcter and Gamble
studies in Gingivitis4423
open to participants now80
phase 3 studies under way50
reach primary completion within a year50
programswith a study of their own here in two years, as the Gingivitis page lists them154

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseColgate PalmoliveProcter and Gamble
Phase 100%00%
Phase 200%

Procter and Gamble: 1 of its 4 programs at phase 2

  1. Sodium Fluoridephase 2
25%
Phase 367%00%
Approved, new studies

Colgate Palmolive: 5 of its 15 programs at approved, new studies

  1. Tin Fluoridesapproved, new study
  2. cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwashapproved, new study
  3. sodium fluoride 5000 ppmapproved, new study
  4. sodium monofluorophosphate toothpasteapproved, new study
  5. Cetylpyridiniumapproved, new study
33%

Procter and Gamble: 3 of its 4 programs at approved, new studies

  1. Tin Fluoridesapproved, new study
  2. Test Stannous Fluoride Dentifriceapproved, new study
  3. Cetylpyridiniumapproved, new study
75%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Colgate Palmolive6 readouts · 6 phase 3

Colgate Palmolive, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Colgate SNaP Total 10/10, 1.5 Tauratephase 3 · Nov 0 · NCT07605338
·

Colgate Palmolive, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. 0.45% SnF HW with NaF (1450 F)phase 3 · Jan 0 · NCT07842991
··

Colgate Palmolive, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Silica Free Meridolphase 3 · Apr 0 · NCT07842978
····

Colgate Palmolive, Sep ’27: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwashapproved, new study · Sep 0 · NCT07807397
  2. sodium fluoride 5000 ppmapproved, new study · Sep 0 · NCT07807397
  3. Tin Fluoridesapproved, new study · Sep 0 · NCT07807397
·
Procter and Gamble0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Colgate Palmolive

New programs 5

Study stopped 0

None

Primary completion later 0

None

Procter and Gamble

New programs 0

None

Study stopped 0

None

Primary completion later 0

None

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Colgate Palmolive 0 of 15 · Procter and Gamble 0 of 4 programs. Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • Within Gingivitis: a program counts when one of its company’s studies of the last two years names Gingivitis as its condition, as the condition page counts it; its phase and next readout are its studies’ here. Stage, biomarker and line of therapy are not read yet.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.